Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 27, 2022 16:01 ET | Source: Travere Therapeutics, Inc.

Travere Therapeutics Reports Third Quarter 2022 Financial Results

EMA accepted for review the Conditional Marketing Authorization application for sparsentan for IgAN in Europe; review decision expected in second half of 2023 New PDUFA target action date for...